Table 2.
Plasma lipid levels in human apoA-I transgenic mice following treatment with nevirapine or efavirenz during the course of the study. All values, in mg/dl, are mean (SD).
| Total Cholesterol | Non-HDL Cholesterol | HDL Cholesterol | ApoA-I | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Week 4 | Week 8 | Baseline | Week 4 | Week 8 | Baseline | Week 4 | Week 8 | Baseline | Week 4 | Week 8 | |
| Control | 169 (21) | 245 (27) | 275 (49) | 34 (9) | 64 (68) | 76 (18) | 135 (17) | 180 (22) | 200 (32) | 294 (21) | 408 (23) | 364 (24) |
| Efavirenz | 163 (14) | 302* (51) | 304 (22) | 38 (6) | 79* (55) | 80 (12) | 125 (14) | 223* (51) | 224 (18) | 269 (20) | 440 (53) | 361 (22) |
| Nevirapine | 165 (13) | 281* (38) | 258 (32) | 41 (14) | 58 (97) | 66 (14) | 124 (23) | 224* (38) | 192 (20) | 285 (25) | 441 (40) | 351 (18) |
*
P < 0.05 vs. corresponding to control